Christopher Barnum

Abstract Alzheimer’s disease (AD) involves chronic neuroinflammation driven by tumor necrosis factor (TNF). XPro1595 selectively neutralizes pathological soluble TNF while preserving neuroprotective transmembrane TNF signaling. MINDFuL (clinicaltrials.gov NCT05318976, registration April 1st 2022) was a Phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study.

A hypothesis-driven approach to pro- and anti-inflammatory proteins in Alzheimer's disease Neuroinflammation has been strongly associated with AD, and as such, efforts have been made to obtain discrete CSF measures of inflammatory proteins for both diagnostic and prognostic purposes; however, such discrete measures may fail to account for overlapping disease pathways and the relationships between them.

The biopharmaceutical industry continues to invest heavily in technologies for identification of predictive biomarkers. Drug developers want not only to find quantitative evidence that their therapies will work as designed, but also to anticipate which patient populations will respond positively to those regimens. Doing that could streamline clinical trials, accelerate approvals, and ultimately improve patient outcomes.